DeCure for Alpha thalassemia-intellectual disability syndrome type 1
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for alpha thalassemia-intellectual disability syndrome type 1 — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAlpha thalassemia-intellectual disability syndrome type 1 maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for alpha thalassemia-intellectual disability syndrome type 1 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
alpha hemoglobin stabilizing protein (AHSP) — AHSP is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet hemdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1Z8U · 2.4 Å · ligand PROTOPORPHYRIN IX CONTAINING FE (HEM). Experimental structure, not a prediction.
What the evidence adds up to
Alpha-thalassemia-intellectual disability syndrome type 1 is not mentioned in any of the four abstracts provided. The abstracts cover thalassemia generally, alpha-thalassemia as a haemoglobin disorder, and neurocognitive outcomes in children with beta-thalassemia and sickle beta-thalassemia, but none address the specific syndromic form that combines alpha-thalassemia with intellectual disability. One 2005 review notes that children with beta-thalassemia major and intermedia and children with sickle beta-thalassemia are at substantial risk for silent brain infarcts that may cause neurocognitive impairment similar to that seen in sickle cell anaemia, and recommends neuropsychological screening and early intervention. No drug treatment or repurposing is discussed in that abstract.
A 2023 overview of alpha-thalassemia describes it as the commonest hereditary monogenic disease worldwide, caused by loss of alpha-globin genes, and categorises it into alpha-thalassemia 1 (both genes on one chromosome inactivated) and alpha-thalassemia 2 (one gene active). The clinical phenotype depends on the degree of gene impairment. No drug therapy or repurposing is mentioned. A 2017 study of 156 anaemic US veterans found that 5% had alpha0-thalassemia (loss of two alpha globin genes), 26% had alpha+-thalassemia (loss of one), and 69% were negative. That study proposes DNA analysis for mild anaemia of uncertain cause but does not address intellectual disability or any treatment.
The 2024 position statement from the Thalassaemia International Federation argues that thalassemia is not currently considered a disability per se but can become disability-inducing if poorly treated or as complications accumulate with age. It proposes a disability risk assessment model (DRAM-Thal) based on a literature review and a 2022–2023 survey, and calls for further research on how the condition affects rights and daily life. No drug, intervention, or repurposing is discussed. What is still missing for alpha-thalassemia-intellectual disability syndrome type 1 specifically is any clinical trial, any drug tested in that population, any patient stratification based on genotype, and any funding directed at this rare syndromic form rather than thalassemia in general.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Annals of the New York Academy of Sciences · 2005 · 22 citations
Thalassemia and Learning: Neurocognitive Functioning in Children
AbstractAs more effective management and even cure of thalassemia become possible, attention is beginning to be directed to the potential neurologic and resulting neurocognitive effects of this illness on adults and children. Recent studies indicate that for adults with beta-thalassemia major and intermedia, and for children with sickle beta-thalassemia (Sbeta-thalassemia), there is a substantial risk for silent brain infarcts that may be associated with neurocognitive impairment similar to that reported for children with sickle cell anemia. Here the available literature in this area is reviewed and the limited outcomes are compared with those available from large, multicenter longitudinal studies of sickle cell anemia. On the basis of these comparisons, it is recommend that children with thalassemia be screened for specific neuropsychological impairments and that they be provided early intervention and special education access as available under the Individuals with Disabilities Education Act (IDEA) or the 504 Regulations of the Rehabilitation Act of 1973.
European Journal Of Haematology · 2024 · 2 citations · open access
Assessing Disability in Thalassaemia: A Position Statement by the Thalassaemia International Federation
AbstractThalassemia is not currently conceived per se as a disability, but it can be a disability-inducing condition if poorly treated or as complications increase with age. People living with thalassemia do not wish, on the one hand, to be considered disabled persons to avoid stigma and loss of opportunities to achieve social inclusion in all paths of life while, on the other, they are in need of lifelong appropriate, disease-specific health and social care, including disability allowances and schemes, in order to be able to smoothly integrate into society and achieve professional, educational, personal, and social goals. The ongoing debate on whether thalassemia is a disability or not is thus complex and inconclusive and has created a vast heterogeneity of policies and approaches across the globe. Given that the risk to develop disabilities is subject to individualised assessment, the thalassemia International Federation (TIF) proposes a specific disability risk assessment model for thalassaemia (DRAM-Thal), based on the findings of a targeted literature review and of the TIF survey 2022-2023. This model considers both clinical features and social parameters and is addressed to national healthcare and social services and all other relevant stakeholders. At the same time, this work prompts further research on this understudied topic that heavily affects the rights and daily life of people living with the disease.
Scholars Journal of Applied Medical Sciences · 2023 · 1 citations · open access
Alpha- Thalassemia: An Overview
AbstractAlpha-Thalassemia is the commonest hereditary monogenic disease worldwide. α-thalassemia is caused by α-globin gene losses and categorized into α-thalassemia 1 and α-thalassemia 2 depending on how many α-globin genes are functioning. Α thalassemia 1 is defined by inactivation of both α-globin genes on a chromosome, while in α-thalassemia 2, one gene is active. The clinical phenotype depends on the degree of genes impairment. This review will present an overview of α-thalassemia, its incidence, causes, and clinical characterization, and discuss different laboratory techniques used for the diagnosis.
Zenodo (CERN European Organization for Nuclear Research) · 2017 · 0 citations · open access
The Prevalence of alpha-Thalassemia in Anemic US Veterans without Nutritional Deficiency or Abnormal Hemoglobin HPLC Pattern
AbstractAlpha-thalassemia is one of the most common hemoglobin genetic abnormalities. The primary defect is the reduced or absent production of the alpha globin chains, which underlines 4 clinical conditions: 1) alpha+-thalassemia (loss of one alpha globin), 2) alpha0-thalassemia (loss of 2 alpha globins), 3) HbH disease (loss of 3 alpha globins), and 4) Hb Bart hydrops fetalis syndrome (loss of all alpha globins). Among the anemic US veteran patients, one subpopulation defies extensive workup and remains etiology unknown (normal status of iron, VitB12, and Folate, normal hemoglobin HPLC pattern, etc.). Here we present the data of alpha-thalassemia DNA analysis in this subpopulation. 156 patients were analyzed of the alpha-globin gene locus by multiplex ligation-dependent probe amplification (LabCorp, RTP, NC). The prevalence of alpha0-thalassemia was 5%, alpha+-thalassemia 26%, and negative 69%. We believe alpha-thalassemia DNA analysis might be a useful test choice in mild anemic patients with uncertain etiology.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
